Medios AG Logo

Medios AG

ILM1 | F

Overview

Corporate Details

ISIN(s):
DE000A1MMCC8 (+1 more)
LEI:
391200Z7Z09IHDBT2L23
Country:
Germany
Address:
Heidestraße 9, 10557 Berlin
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Medios AG is a leading European specialty pharmaceutical company focused on advancing individualized medicine. The company's core business involves the compounding of patient-specific therapies and the supply of specialty pharma solutions. It serves a diverse client base, including pharmacies, medical specialists, hospitals, and pharmaceutical companies, ensuring reliable access to innovative treatments for complex and chronic conditions. With a strong focus on therapeutic areas such as oncology, neurology, and autoimmune diseases, Medios pioneers the development and distribution of advanced therapies and biotechnological precision medicine. By integrating pharmaceutical supply with specialized compounding services, the company plays a crucial role in making personalized treatments accessible to patients.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Medios AG. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-28 10:15
Declaration of Voting Results & Voting Rights Announcements
English 13.5 KB
2025-08-27 10:37
Declaration of Voting Results & Voting Rights Announcements
English 13.2 KB
2025-08-13 07:37
Earnings Release
Medios accelerates growth in the first half of 2025 and significantly increases…
English 20.0 KB
2025-08-13 00:00
Interim Report
Half-yearly financial report 2025
English 500.4 KB
2025-07-18 11:41
Major Shareholding Notification
English 5.4 KB
2025-07-11 09:55
Transaction in Own Shares
Medios successfully completes public share buyback offer
English 11.0 KB
2025-06-18 19:16
Transaction in Own Shares
Medios adopts public share buyback offer for up to 1 million shares at a price …
English 11.8 KB
2025-05-27 16:06
Post-Annual General Meeting Information
Medios AG Annual General Meeting 2025: Shareholders approve all proposed resolu…
English 10.1 KB
2025-05-14 07:50
Earnings Release
Medios starts 2025 financial year successfully with significant increase in ear…
English 20.7 KB
2025-05-13 00:00
Quarterly Report
Q1 statement / Q1 financial report 2025
English 10.1 MB
2025-05-12 18:58
Board/Management Information
Medios repositions itself for the next phase of its corporate development
English 12.7 KB
2025-04-14 15:06
Pre-Annual General Meeting Information
Medios AG: Bekanntmachung der Einberufung zur Hauptversammlung am 27.05.2025 in…
German 256.2 KB
2025-03-25 07:50
Earnings Release
Medios expects further growth in revenue and earnings after record year 2024
English 20.3 KB
2025-03-25 00:00
Annual Report
Annual financial report 2024
English 4.1 MB
2025-03-05 08:50
Earnings Release
Preliminary figures for Medios AG 2024: Significant increase in earnings and ma…
English 12.3 KB

Automate Your Workflow. Get a real-time feed of all Medios AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Medios AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-19 van Rietschoten, Constantijn Board Buy None 162,805.82 EUR
2023-06-28 Prußeit, Christoph Board Buy None 39,100.00 EUR
2021-12-09 Miehler, Mi-Young Board Other None 3,550,000.00 EUR
2021-12-09 Prußeit, Christoph Board Other None 1,775,000.00 EUR
2021-12-09 Miehler, Mi-Young Board Other None 700,000.00 EUR
2021-12-09 Prußeit, Christoph Board Other None 350,000.00 EUR

Peer Companies

Company Country Ticker View
Antibiotice S.A. Logo
Manufactures FDA-approved generic drugs, sterile injectables, and APIs for global markets.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway ABS
ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway AZT
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands 1AE
Japan 4886
Astellas Pharma Inc. Logo Japan 4503
AstraZeneca PLC Logo
A global biopharma firm developing medicines for oncology, rare diseases, and biopharmaceuticals.
United Kingdom AZN
Bachem Holding AG Logo
A CDMO developing and manufacturing peptides and oligonucleotides for pharma and biotech.
Switzerland BANB